Clontarf Energy Share Discussion Threads

[nicky21] 28/6/2018 18:37

come on guys be honest for a change.you can still make money here if Ghana comes in and you average dowm.

they get Ratification then it will be followed by a farmout.

in the mean time just be patient.

[dave4545] 28/6/2018 17:08

Yeah I remember holding a share 15 years ago and on the thread here on advfn a certain poster by the name TOPINFO turned up on the same thread with amazing ramping for one day then vanished and never showed up again.
Who would think 15 years later he is still doing it via twitter and has thousands of mugs that think he still holds shares more than 1 hour

[nicky21] 28/6/2018 16:23

dave4545 they bought because of the AGM tom and with DH being in Ghana this week.

[dave4545] 28/6/2018 16:15

NR

95% of the chasers this morning all lost substantial amounts in relation to what they put in.

Buying stocks for 0.28p then selling for 0.21p 10 minutes later means you will lucky to last a week before you are wiped out, these people probably did the same yesterday with PREM

[nicky21] 28/6/2018 16:04

i mean long term

[nicky21] 28/6/2018 16:03

with clon at these prices you can make monies.

[nick rubens] 28/6/2018 16:01

AIM is a desperate place. If you don't make money on a lucky day trade punt then it's unlikely you'll make any at all it seems.

[nicky21] 28/6/2018 15:04

i think expect Ghana update tom.
hence the speculative buying today.

[nicky21] 28/6/2018 14:57

this used to be the old persian gold..then they went into south america and screwed up..

and now they are really after this Ghana block.
they are not giving up.

[nicky21] 28/6/2018 14:55

on ratification this could hit 1.5p/2p

on farmout 3p...and then on the drill bit anything is possible.
its those who bought at 4p/5p who are moaning.

well why not average down at these prices.

[chiefbrody] 28/6/2018 14:49

Only another 5000% or so to get back to its placing price lol.

[nicky21] 28/6/2018 14:46

am not ramping.
just telling inestors how cheap it is.

[nicky21] 28/6/2018 14:25

just hope something positive is announced at the AGM tomorrow.

[nicky21] 28/6/2018 14:22

even at 3p you make 1500%...

that could be over 24 months.

[nicky21] 28/6/2018 14:15

on ratification 1.5p/2p
on farmout 3p.
expect a placing in between.

not for widows or orphans though

[nicky21] 28/6/2018 13:49

WE MUST BE CLOSE NOW.




Recent changes in government has returned to power the party who first made the agreement with us. There is now renewed energy to attempt to finalise a deal. While there is goodwill on both sides, actually concluding a deal has been difficult.

[nicky21] 28/6/2018 13:23

you going Currypasty?

whose going??

[nicky21] 28/6/2018 13:22

we have a big big seller who wants out.

[currypasty] 28/6/2018 13:20

The Company's Annual General Meeting will be held on Friday 29(th) June 2018 at Hilton Paddington Hotel, 146 Praed Street, London, W2 1EE at 10:30 am.

[nicky21] 28/6/2018 13:18

no deramp intended..

you can buy as many as you like ONLINe but will struggle to sell small quantities

[nicky21] 28/6/2018 12:47

hxxp://www.clontarfenergy.com/projects/ghana_.aspx

Potential : multi-billion barrel recoverable

[1lilac] 28/6/2018 12:47

Chaps

Farn just moved 10%. delayed reaction.



Faron Pharmaceuticals Oy Clevegen successful toxicity studies
28/06/2018 7:01am
RNS Non-Regulatory

TIDMFARN

Faron Pharmaceuticals Oy

28 June 2018

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Clevegen shows good safety and potential to block Clever-1 on circulating monocytes

-- Wholly-owned Clevegen (FP-1305) shows no toxicity in dose escalation studies in large preclinical models

-- The no-observed-adverse-effect-level (NOAEL) was 100 mg/kg, which is roughly 30 times higher concentration than needed for Clever-1 occupancy in vivo

-- Clevegen also blocked Clever-1 on circulating monocytes as expected. The duration of blocking was dose dependent and resumed to normal level in 20 days in the highest dose

-- The Company expects CTA filing for MATINS study in Q3 2018 and first patient recruitment in Q4 2018

TURKU - FINLAND, 28 June 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, today announces successful toxicity studies and control of blood Clever-1 positive monocytes, precursor cells to tumour associated macrophages (TAM) in large preclinical models.

The toxicity studies were designed to fulfil regulatory requirements for 3-week interval intravenous administration of Clevegen, typical for other anti-cancer antibodies currently in use. FP-1305 is a humanized IgG4 monoclonal antibody produced in CHO -cells by Faron collaborator Abzena. The FP-1305 drug product in its final formulation was administered as a single dose at 3, 30 and 100 mg/kg.

No toxicologically relevant changes were observed in any subject. No major changes were observed after treatment with FP-1305 in T lymphocytes subsets. The binding of Clevegen to its receptor on circulating CD14+ monocytes was confirmed by investigating the receptor occupancy, the recovery of which occurred between 3 to 20 days after dosing in a dose-dependent manner. No relevant changes were present in cytokines and no anti-drug antibodies (ADA) were detected in any subject. Therefore, the highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL).